Substance-P antagonists: a new treatment for depression?
Nutt
D
D
Psychopharmacology Unit, University of Bristol, School of Medical Sciences, UK.
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D000077608:Aprepitant; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D017374:Paroxetine / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013373:Substance P / Q000037:antagonists & inhibitors*
D018687:Antidepressive Agents, Second-Generation; D000077608:Aprepitant; D009025:Morpholines; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013373:Substance P